BNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

BNP Paribas Financial Markets purchased a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 95,424 shares of the company's stock, valued at approximately $532,000. BNP Paribas Financial Markets owned approximately 0.21% of 4D Molecular Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in FDMT. Peapod Lane Capital LLC acquired a new position in 4D Molecular Therapeutics in the fourth quarter worth about $806,000. Rhumbline Advisers raised its position in 4D Molecular Therapeutics by 5.3% in the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock worth $409,000 after purchasing an additional 3,675 shares in the last quarter. Proficio Capital Partners LLC increased its holdings in shares of 4D Molecular Therapeutics by 100.0% during the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock worth $111,000 after buying an additional 10,000 shares in the last quarter. M&T Bank Corp increased its holdings in shares of 4D Molecular Therapeutics by 98.9% during the fourth quarter. M&T Bank Corp now owns 37,487 shares of the company's stock worth $209,000 after buying an additional 18,639 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $629,000. Institutional investors and hedge funds own 99.27% of the company's stock.

4D Molecular Therapeutics Trading Up 0.9%

Shares of 4D Molecular Therapeutics stock traded up $0.03 during midday trading on Wednesday, reaching $3.45. The company had a trading volume of 209,606 shares, compared to its average volume of 831,507. The company has a market capitalization of $159.82 million, a price-to-earnings ratio of -1.21 and a beta of 2.87. The stock has a fifty day simple moving average of $3.24 and a 200 day simple moving average of $4.87. 4D Molecular Therapeutics, Inc. has a 1-year low of $2.24 and a 1-year high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). Sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on FDMT shares. Barclays dropped their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, May 9th. The Goldman Sachs Group dropped their price objective on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Finally, Chardan Capital dropped their price objective on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.56.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.